A breakthrough in the treatment of ovarian cancer has brought hope to patients facing this challenging disease. According to Wales Online, a new combination of drugs has shown remarkable results in women with low-grade serous ovarian cancer, a type that typically does not respond well to chemotherapy. Almost a third (31%) of these women experienced shrinkage or halted growth of their tumours when taking a combination of avutometinib and defactinib.
The success was even more striking for patients with a mutation in the KRAS gene, with 44% seeing their tumours shrink. The trial, led by Professor Susana Banerjee from the Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, London, has raised hopes for changing treatment approaches globally for this type of cancer. The new drugs being tested, developed by Verastem Oncology, have shown promising results with lower toxicities and fewer side effects compared to conventional treatments.
The data from the study, presented at the International Gynaecologic Cancer Society’s meeting in Dublin, revealed that 31% of patients with low-grade serous ovarian cancer experienced tumour shrinkage or growth stoppage, a significant improvement compared to traditional chemotherapy or hormone therapies. Low-grade serous ovarian cancer is a rare and hard-to-treat form of the disease, often affecting younger women and showing resistance to standard treatments.
Both avutometinib and defactinib work by blocking signals that promote cancer cell growth, offering new hope to patients with limited treatment options. The positive outcomes from the trial have sparked excitement among experts, prompting further research in a phase three trial to potentially establish a new standard of care for recurrent low-grade serous ovarian cancer.